Periodic Reporting for period 4 - MultiViVax (Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria)

Plasmodium vivax accounts for 100-400 million clinical malaria cases each year among 2.5 billion people living at risk. The Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria and calls for a vaccine intervention to achieve 75% efficacy over...